—

Zealand Pharma A/S (ZEAL.CO) — Technical state

As of 2026-11-16 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 59 out of 100 (momentum 14 · quality 74 · valuation 76), as of 2026-11-18.
  • Signal: Stochastic turned down — Its stochastic crossed down from overbought (%K 63.9 under %D 72) 3 sessions ago — momentum is cooling. (as of 2026-11-16)
  • Trend: Zealand Pharma A/S trades 4.6% below its 50-day and 20.1% below its 200-day moving average. (as of 2026-11-16)
  • Index seat: HALO Growth 100

Zealand Pharma develops peptide-based medicines for gastrointestinal and metabolic conditions, operating from Denmark with a further base in the United States. Its marketed products include an injector treatment for severe low blood sugar and a dual-hormone system pairing insulin with a glucagon-like peptide for an artificial pancreas approach.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the ZEAL.CO overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Stochastic turned down

Its stochastic crossed down from overbought (%K 63.9 under %D 72) 3 sessions ago — momentum is cooling.

The moving-average stack

FAQ · from the current data · as of 2026-11-16

Quick answers

What is the current Closelooknet signal on ZEAL.CO?

Stochastic turned down — Its stochastic crossed down from overbought (%K 63.9 under %D 72) 3 sessions ago — momentum is cooling. As of 2026-11-16; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is ZEAL.CO above its 50-day and 200-day moving averages?

As of 2026-11-16, Zealand Pharma A/S trades -4.6% below its 50-day and -20.1% below its 200-day average, with the 20-day +2.1% away.

How far is ZEAL.CO from its 52-week high?

56.9% below the 52-week high and 8.7% above the 52-week low, as of 2026-11-16.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.